WO2001002018A3 - Intermolekular assoziierende verbindungen und diese umfassende aggregate - Google Patents

Intermolekular assoziierende verbindungen und diese umfassende aggregate Download PDF

Info

Publication number
WO2001002018A3
WO2001002018A3 PCT/EP2000/006139 EP0006139W WO0102018A3 WO 2001002018 A3 WO2001002018 A3 WO 2001002018A3 EP 0006139 W EP0006139 W EP 0006139W WO 0102018 A3 WO0102018 A3 WO 0102018A3
Authority
WO
WIPO (PCT)
Prior art keywords
integer
bond
hydrogen
represent
different
Prior art date
Application number
PCT/EP2000/006139
Other languages
English (en)
French (fr)
Other versions
WO2001002018A2 (de
Inventor
Nikolai Vladimirovich Bovin
Alexandr Borisovich Tusikov
Alexandr Alexandrovic Chinarev
Mariya Alexandrovna Dicusar
Alexandra Sergeevna Gambariyan
Valentina Petrovna Marinina
Original Assignee
Syntesome Ges Fuer Medizinisch
Nikolai Vladimirovich Bovin
Alexandr Borisovich Tusikov
Alexandr Alexandrovic Chinarev
Mariya Alexandrovna Dicusar
Alexandra Sergeevna Gambariyan
Valentina Petrovna Marinina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntesome Ges Fuer Medizinisch, Nikolai Vladimirovich Bovin, Alexandr Borisovich Tusikov, Alexandr Alexandrovic Chinarev, Mariya Alexandrovna Dicusar, Alexandra Sergeevna Gambariyan, Valentina Petrovna Marinina filed Critical Syntesome Ges Fuer Medizinisch
Priority to US10/019,902 priority Critical patent/US7294615B1/en
Priority to CA2376164A priority patent/CA2376164C/en
Priority to EP00949235A priority patent/EP1223984A2/de
Priority to JP2001507508A priority patent/JP2003503465A/ja
Priority to AU62669/00A priority patent/AU6266900A/en
Publication of WO2001002018A2 publication Critical patent/WO2001002018A2/de
Publication of WO2001002018A3 publication Critical patent/WO2001002018A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)

Abstract

Verbindung der allgemeinen Formel (I): X(B)m, wobei X für eine m-wertige Einheit steht und die B gleich oder verschieden sind und für K-R stehen, wobei K für eine Bindung oder für A?1-(A2-A3)¿k-sp steht, wobei A1 für (CH¿2?)tY(CH2)u steht, wobei Y für ⊃C=O, ⊃NH, -O-, -S- oder eine Bindung, t für eine ganze Zahl von 0 bis 6 und u für eine ganze Zahl von 0 bis 6 steht, A?2¿ für -NHCO-, -CONH-, -OCONH- oder SCONH- steht, oder für -CO- steht, A3 für (CH¿2?)r, O(CH2)r, NH(CH2)r, S(CH2)r, oder -(CHQ)- steht, wobei r für eine ganze Zahl von 1 bis 6 und Q für eine substituierte oder unsubstituierte Alkyl- oder Aryl- Gruppe steht, sp für einen zweiwertigen Spacer oder eine Bindung steht, und k für eine ganze Zahl von 5 bis 100 steht, und R für Wasserstoff, einen zur spezifischen Bindung an einen Rezeptor geeigneten Liganden, ein Marker-Molekül oder eine katalytisch aktive Gruppe steht, und m mindestens 2 ist, mit der Massgabe, dass (1) in der Verbindung mindestens ein R nicht Wasserstoff ist, (2) mindestens zwei K vorliegen, die nicht für eine Bindung stehen, und (3) X, die B und m so gewählt sind, dass eine intermolekulare Assoziation der K in flüssiger Phase durch Bildung von Wasserstoffbrücken-Bindungen unter Ausbildung von Aggregaten, die auf der Oberfläche mehrere R präsentieren, die nicht Wasserstoff sind, möglich ist, und (4) die Molmasse des Fragments X(K)m weniger als 20.000 beträgt.
PCT/EP2000/006139 1999-06-30 2000-06-30 Intermolekular assoziierende verbindungen und diese umfassende aggregate WO2001002018A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/019,902 US7294615B1 (en) 1999-06-30 2000-06-30 Compounds that associate on the intermolecular level and aggregate bodies that contain them
CA2376164A CA2376164C (en) 1999-06-30 2000-06-30 Intermolecularly associating compounds, and aggregates comprising them
EP00949235A EP1223984A2 (de) 1999-06-30 2000-06-30 Intermolekular assoziierende verbindungen und diese umfassende aggregate
JP2001507508A JP2003503465A (ja) 1999-06-30 2000-06-30 分子間で会合した化合物とこれらの化合物を含む凝集体
AU62669/00A AU6266900A (en) 1999-06-30 2000-06-30 Compounds that associate on the intermolecular level and aggregate bodies that contain them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19930177.8 1999-06-30
DE19930177A DE19930177B4 (de) 1999-06-30 1999-06-30 Intermolekular assoziierende Verbindungen und deren Verwendung

Publications (2)

Publication Number Publication Date
WO2001002018A2 WO2001002018A2 (de) 2001-01-11
WO2001002018A3 true WO2001002018A3 (de) 2002-03-14

Family

ID=7913194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006139 WO2001002018A2 (de) 1999-06-30 2000-06-30 Intermolekular assoziierende verbindungen und diese umfassende aggregate

Country Status (7)

Country Link
US (1) US7294615B1 (de)
EP (1) EP1223984A2 (de)
JP (1) JP2003503465A (de)
AU (1) AU6266900A (de)
CA (1) CA2376164C (de)
DE (1) DE19930177B4 (de)
WO (1) WO2001002018A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CA2740554C (en) * 2008-10-13 2016-12-20 Nikolai Vladimirovich Bovin Multiligand constructs
IT1396620B1 (it) * 2009-11-25 2012-12-14 Therapicon Srl Analoghi chimerici
CA2940579A1 (en) 2014-03-13 2015-09-17 Universitaet Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
EP3101012A1 (de) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Neue gadoliniumchelat-verbindung zur verwendung in der magnetresonanzbildgebung
EP3350193B1 (de) 2015-09-16 2020-12-23 Universität Basel An antikörper gegen glycoepitope von glycosphingolipiden bindende kohlenhydratliganden
RU2612221C1 (ru) * 2015-12-16 2017-03-03 Общество с ограниченной ответственностью "Синтавр" Блокаторы вируса гриппа
JP7034160B2 (ja) 2016-11-28 2022-03-11 バイエル・ファルマ・アクティエンゲゼルシャフト 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物
PE20211471A1 (es) 2018-11-23 2021-08-05 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0601417A2 (de) * 1992-12-11 1994-06-15 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
WO2000055149A1 (en) * 1999-03-12 2000-09-21 Biota Scientific Management Pty. Ltd. Dimeric compounds and as inhibitors of neuraminidase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278506B6 (en) * 1985-01-04 1997-08-06 Jindrich Kopecek THE POLYMERIC DRUG AND PREPARATION METHOD THEREOF m cells.
US5243035A (en) 1990-02-27 1993-09-07 Drug Delivery System Institute, Ltd. Sialic acid-containing glycolipid derivatives
WO1993017033A1 (en) 1992-02-19 1993-09-02 The Biomembrane Institute Inhibition of cell adhesion by chemically-defined oligosaccharides, their derivatives, mimetics, and antibodies directed thereto
ZA937034B (en) 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US5837689A (en) 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
BR9607098B8 (pt) 1995-02-27 2014-11-18 Gilead Sciences Inc Composto e composição farmacêutica.
US5780606A (en) 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
DE19640791A1 (de) * 1996-10-02 1998-04-16 Syntesome Ges Fuer Medizinisch Glycokonjugate als Inhibitoren der viralen Zelladhäsion
JP2001501620A (ja) * 1996-10-04 2001-02-06 デメジェン インコーポレイテッド 免疫不全ウイルス感染の治療方法
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0601417A2 (de) * 1992-12-11 1994-06-15 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
WO2000055149A1 (en) * 1999-03-12 2000-09-21 Biota Scientific Management Pty. Ltd. Dimeric compounds and as inhibitors of neuraminidase

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CHOI S -K ET AL: "GENERATION AND IN SITU EVALUATION OF LIBRARIES OF POLY(ACRYLIC ACID) PRESENTING SIALOSIDES AS SIDE CHAINS AS POLYVALENT INHIBITORS OF INFLUENZA-MEDIATED HEMAGGLUTINATION", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, vol. 119, no. 18, 7 May 1997 (1997-05-07), pages 4103 - 4111, XP002068481, ISSN: 0002-7863 *
CHOW H -F ET AL: "The Synthesis and Properties of Novel Functional Dendritic Molecules", TETRAHEDRON,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM,NL, vol. 54, no. 30, 23 July 1998 (1998-07-23), pages 8543 - 8660, XP004124033, ISSN: 0040-4020 *
FEOFANOV A V ET AL: "Study of sialylated neoglycoconjugates by surface-enhanced Raman scattering spectroscopy.", BIOORGANICHESKAYA KHIMIYA, vol. 23, no. 11, November 1997 (1997-11-01), pages 910 - 918, XP001002502, ISSN: 0132-3423 *
GAMBARYAN A S ET AL: "SPECIFICATION OF RECEPTOR-BINDING PHENOTYPES OF INFLUENZA VIRUS ISOLATES FROM DIFFERENT HOSTS USING SYNTHETIC SIALYLGLYCOPOLYMERS: NON-EGG-ADAPTED HUMAN H1 AND H3 INFLUENZA A AND INFLUENZA B VIRUSES SHARE A COMMON HIGH BINDING AFFINITY FOR 6'-SIALYL(N-ACETYLLACTOSAMINE)", VIROLOGY, ACADEMIC PRESS, US, vol. 232, no. 2, 9 June 1997 (1997-06-09), pages 345 - 350, XP002068479, ISSN: 0042-6822 *
KRETZSCHMAR G ET AL: "Oligosaccharide Recognition by Selectins: Synthesis and Biological Activity of Multivalent Sialyl Lewis-X Ligands", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 51, no. 47, 20 November 1995 (1995-11-20), pages 13015 - 13030, XP004104680, ISSN: 0040-4020 *
NISHIMURA SHIN-ICHIRO ET AL: "Chemoenzymic preparation of a glycoconjugate polymer having a sialyloligosaccharide: Neu5Ac-alpha(2 fwdarw 3)Gal-beta(1 fwdarw 4)GlcNAc.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 199, no. 1, 1994, pages 249 - 254, XP002175210, ISSN: 0006-291X *
REUTER J D ET AL: "INHIBITION OF VIRAL ADHESION AND INFECTION BY SIALIC-ACID- CONJUGATED DENDRITIC POLYMERS", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 10, no. 2, March 1999 (1999-03-01), pages 271 - 278, XP000804253, ISSN: 1043-1802 *
REUTER J ET AL: "Sialic acid conjugated dendritic polymers inhibit influenza virus binding to target cells in a structural and virus strain-specific manner.", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 98, 1998, & 98th General Meeting of the American Society for Microbiology;Atlanta, Georgia, USA; May 17-21, 1998, 1998, pages 51, abstract no. A-77, XP001002424, ISSN: 1060-2011 *
ROY R ET AL: "SOLID-PHASE SYNTHESIS OF DENDRITIC SIALOSIDE INHIBITORS OF INFLUENZA A VIRUS HAEMAGGLUTININ", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS,GB,CHEMICAL SOCIETY. LETCHWORTH, no. 24, 21 December 1993 (1993-12-21), pages 1869 - 1872, XP000616525, ISSN: 0022-4936 *
UNVERZAGT C ET AL: "CHEMICAL AND ENZYMATIC SYNTHESIS OF MULTIVALENT SIALOGLYCOPEPTIDES", CARBOHYDRATE RESEARCH,NL,ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, vol. 251, 1994, pages 285 - 301, XP002068480, ISSN: 0008-6215 *
WU W -Y W -Y ET AL: "Synthesis of a polymeric 4-N-linked sialoside which inhibits influenza virus hemagglutinin", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 10, no. 4, February 2000 (2000-02-01), pages 341 - 343, XP004189928, ISSN: 0960-894X *
YAMADA K ET AL: "High performance polymer supports for enzyme-assisted synthesis of glycoconjugates", CARBOHYDRATE RESEARCH,NL,ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, vol. 305, no. 3-4, 1 December 1997 (1997-12-01), pages 443 - 461, XP004131532, ISSN: 0008-6215 *
ZANINI D ET AL: "NOVEL DENDRITIC ALPHA-SIALOSIDES: SYNTHESIS OF GLYCODENDRIMERS BASED ON A 3,3'-IMINOBIS(PROPYLAMINE) CORE", JOURNAL OF ORGANIC CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, vol. 61, no. 21, 18 October 1996 (1996-10-18), pages 7348 - 7354, XP002042912, ISSN: 0022-3263 *

Also Published As

Publication number Publication date
DE19930177A1 (de) 2001-01-11
DE19930177B4 (de) 2007-02-08
CA2376164A1 (en) 2001-01-11
EP1223984A2 (de) 2002-07-24
WO2001002018A2 (de) 2001-01-11
US7294615B1 (en) 2007-11-13
CA2376164C (en) 2011-08-16
JP2003503465A (ja) 2003-01-28
AU6266900A (en) 2001-01-22

Similar Documents

Publication Publication Date Title
WO2001002018A3 (de) Intermolekular assoziierende verbindungen und diese umfassende aggregate
EP1264820A4 (de) Amidverbindungen
WO2002004466A3 (en) Catalyst for asymmetric (transfer) hydrogenation
JP2002542342A5 (de)
Apeloig et al. Do silylenes always dimerize to disilenes? Novel silylene dimers with unusual structures
CA2367368A1 (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
NZ331319A (en) Cyclic amine derivatives that are CCR-3 receptor (chemokine receptor) antagonists, compositions containing them and methods for their use (to combat eosinophil induced diseases).
HUP0101022A1 (hu) Kinolinszármazékok gyógyászati alkalmazása
Hada et al. Theoretical study on the reaction mechanism and regioselectivity of silastannation of acetylenes with a palladium catalyst
DE69008371D1 (de) Zusammensetzungen für strapazierfähige, organische Siliciumverbindungen enthaltende Überzüge.
MXPA04000559A (es) Sistema catalizador que contiene ni (o).
CA2254420A1 (en) Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
MX9605974A (es) Proceso mejorado en la sintesis de n-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)fenil]-n-etilacet amida.
RU2000100807A (ru) Простагландиновые фармацевтические композиции
EP0559893A4 (en) Xanthine derivative
EP0359276A3 (de) Stabilisierte synthetische Harzzusammensetzung
ATE442407T1 (de) Kautschukzusammensetzung für reifen, die ein kupplungsmittel der polythiosulfenamid-gruppe enthält
TW282454B (de)
EP0043858A4 (de) Auf heteroringe substituierte oxoalkanoesäurederivate.
Yoshifuji et al. X-ray structure of a sterically protected 1-aza-3-phospha-allene
DE60225188D1 (de) Kautschukzusammensetzung für reifen, die ein kupplungsmittel mit einer polythiosulfenamid-gruppe enthält
WO2002057224A3 (en) Synthesis and antimicrobial activityof novel dicationic 'reversed amidines'
UA66748C2 (en) Phenyl substituted 4-azasteroids fluroderivatives, methods for the preparation thereof (variants) and pharmaceutical composition based thereon
EP0852241A4 (de) Aminoharzzusammensetzungen
EP1310490A4 (de) Gpr14-antagonisten

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CU CZ DE DK DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000949235

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2376164

Country of ref document: CA

Ref country code: CA

Ref document number: 2376164

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 62669/00

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CU CZ DE DK DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10019902

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000949235

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642